PERSPECTA

News from every angle

← Back to headlines

NorthStrive Biosciences to Test Muscle-Loss Drugs in Microgravity Spaceflight

PMGC Holdings announced a term sheet with Orbit2Orbit to conduct a spaceflight study on NorthStrive’s EL-22 and EL-32 assets targeting microgravity-induced muscle atrophy.

25 Aug, 11:30 — 25 Aug, 11:30
PostShare

Sources

Showing 1 of 1 sources
taiwan-newsMostly Factual8h ago

PMGC Holdings Announces Term Sheet with Orbit2Orbit for NorthStrive Biosciences to Launch a Spaceflight Study of Its Myostatin and Activin A Assets, EL-22 and EL-32, Targeting Microgravity-Induced Muscle Loss - Taiwan News

PMGC Holdings Announces Term Sheet with Orbit2Orbit for NorthStrive Biosciences to Launch a Spaceflight Study of Its Myostatin and Activin A Assets, EL-22 and EL-32, Targeting Microgravity-Induced Muscle Loss  Taiwan News

Read full article →

Related Stories

Grayscale Launches First Zcash ETF, Token Soars

31m ago

SpaceX Plans $100 Billion Starship Spaceport in Louisiana

34m ago

Taiwan Charges Nine for Smuggling AI Servers to China

45m ago

Nvidia Q2 Earnings Anticipation Drives Market Focus on AI and Valuation

48m ago